How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market
- By Therapeutic Application: Rheumatoid Arthritis, Systemic Lupus Erythematosus, B-cell Malignancies, Allergic Diseases, Other Autoimmune Disorders
- By Drug Class: Small Molecule Syk Inhibitors, Biologic Syk Inhibitors
- By Route of Administration: Oral, Intravenous, Subcutaneous
- By Development Stage: Preclinical, Clinical Trials Phase I, Clinical Trials Phase II, Clinical Trials Phase III, Approved and Commercialized
- By End User: Hospitals, Specialty Clinics, Research Institutes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Rheumatoid Arthritis leads By Therapeutic Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 13 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Application 5
Drug Class 2
Route of Administration 3
Development Stage 5
End User 3
Companies profiled
Gilead Sciences (Tirabrutinib)
Rigel Pharmaceuticals (Fostamatinib)
Sanofi (Fostamatinib)
Pfizer (Fostamatinib)
AstraZeneca
Bristol-Myers Squibb
Novartis
Eli Lilly and Company
Johnson & Johnson
AbbVie
Amgen
Merck & Co.
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Gilead Sciences (Tirabrutinib)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Rigel Pharmaceuticals (Fostamatinib)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sanofi (Fostamatinib)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer (Fostamatinib)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AstraZeneca
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bristol-Myers Squibb
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Novartis
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Johnson & Johnson
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AbbVie
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Amgen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Merck & Co.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Bayer
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$12,864M by 2033 · 11.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Rheumatoid Arthritis31.6
- Systemic Lupus Erythematosus18.5
- B-cell Malignancies19.5
- Allergic Diseases14.7
- Other Autoimmune Disorders15.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,756M → $4,356M · 12.0%
Europe$1,224M → $2,805M · 10.9%
Asia Pacific$1,117M → $2,415M · 10.1%
Latin America$691.7M → $1,491M · 10.1%
Middle East and Africa$532.1M → $1,341M · 12.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.622026
11.632027
11.642028
11.652029
11.682030
11.682031
11.692032
11.712033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Gilead Sciences (Tirabrutinib)26.3
- Rigel Pharmaceuticals (Fostamatinib)8.8
- Sanofi (Fostamatinib)9.3
- Pfizer (Fostamatinib)9.8
- AstraZeneca8.0
- Bristol-Myers Squibb9.9
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Application26.7%
Drug Class16.2%
Route of Administration20.5%
Development Stage12.8%
End User23.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.1
- Europe22.6
- Asia Pacific19.5
- Latin America12.0
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Gilead Sciences (Tirabrutinib) | 83 | 93 | 76 | 95 | 98 | 84 | 88 |
| Rigel Pharmaceuticals (Fostamatinib) | 75 | 84 | 84 | 69 | 74 | 74 | 77 |
| Sanofi (Fostamatinib) | 87 | 87 | 69 | 76 | 81 | 69 | 78 |
| Pfizer (Fostamatinib) | 65 | 82 | 69 | 69 | 57 | 79 | 70 |
| AstraZeneca | 57 | 58 | 68 | 67 | 71 | 71 | 65 |
| Bristol-Myers Squibb | 57 | 46 | 59 | 57 | 56 | 65 | 57 |
| Novartis | 43 | 52 | 59 | 44 | 53 | 42 | 49 |
| Eli Lilly and Company | 55 | 57 | 60 | 53 | 46 | 48 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Gilead Sciences (Tirabrutinib)
- Rigel Pharmaceuticals (Fostamatinib)
- Sanofi (Fostamatinib)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Gilead Sciences (Tirabrutinib) | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Rigel Pharmaceuticals (Fostamatinib) | ◐ | ◐ | ◐ | − | ◐ | ✓ |
| Sanofi (Fostamatinib) | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Pfizer (Fostamatinib) | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| AstraZeneca | ◐ | − | ◐ | ◐ | ◐ | ✓ |
| Bristol-Myers Squibb | − | − | ◐ | ◐ | ◐ | ◐ |
| Novartis | ◐ | ◐ | − | − | ◐ | − |
| Eli Lilly and Company | − | − | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Gilead Sciences (Tirabrutinib)88
2Sanofi (Fostamatinib)78
3Rigel Pharmaceuticals (Fostamatinib)77
4Pfizer (Fostamatinib)70
5AstraZeneca65
6Bristol-Myers Squibb57
7Eli Lilly and Company53
8Novartis49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Gilead Sciences (Tirabrutinib)Sanofi (Fostamatinib)
Challenger2
Strong scale, closing on the leaders.
Rigel Pharmaceuticals (Fostamatinib)Pfizer (Fostamatinib)
Contender2
Focused players with pockets of strength.
AstraZenecaBristol-Myers Squibb
Niche2
Specialists in a single segment or region.
NovartisEli Lilly and Company
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Application in North America, then scale across Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market — a $325M beachhead inside a $4.67B market.
Beachhead (SOM)$325Mobtainable near-term
Serviceable (SAM)$1.95Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Rheumatoid Arthritis
Best fit — highest urgency & budget in Therapeutic Application.
Economic buyer76 fit
Systemic Lupus Erythematosus
Strong fit — clear ROI and a fast path to value.
End user67 fit
B-cell Malignancies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel28%
Digital / self-serve23%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified26%
Evaluation13%
Closed-won6%
$13.1KCAC
$77KLTV
5.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market is a high-growth opportunity — $5.76B by 2033, compounding at 10.9%.
TAM · 2025$2.52Btoday
TAM · 2033$5.76Bforecast
CAGR10.9%2027–2033
Cumulative$35.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.76BTotal addressable market
SAM$2.26BServiceable available market
SOM$475MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.9% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Application moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.76BLarge & growingTAM by 2033 at 10.9% CAGR
$2.26BServiceable nowreachable with today’s model
$475MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.49BBear7.1% CAGR
$5.76BBase10.9% CAGR
$7.37BBull14.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market — a $8.69B market by 2033. Plan: grow share from 5.3% to 11.3%.
Market size · 2033$8.69Btotal addressable
Market CAGR9.2%2027–2033
Target share11.3%from 5.3% today
Revenue ambition$982Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.3% | 11.3% | On track |
| Revenue | $502M | $982M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 32.3% | 45.2% | Ahead |
| Customer retention | 88.2% | 94.1% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $137M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market conversation — a $1.12B market you can size, segment and defend in minutes.
Market size · 2033$1.12Btotal opportunity
Growth3.6%CAGR to 2033
Addressable buyers1,222+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Application
Goal Grow share in Therapeutic Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 4 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
Gilead Sciences (Tirabrutinib)Rigel Pharmaceuticals (Fostamatinib)Sanofi (Fostamatinib)Pfizer (Fostamatinib)AstraZenecaBristol-Myers SquibbNovartisEli Lilly and Company+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Spleen Tyrosine Kinase (Syk) Antibody Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportSpirovital Therapy Unit Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportSpirostan-6-one, 3,5-dihydroxy-, (3β,5α,25R) Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportSpironolactone API Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportSpirometry Software Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportSpirometry Machine Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportSpirometer Transducers Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportSpirometer Pipe Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportSpirometer Mouthpiece Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportSpiramycin Drug Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportSpiral Medical Tube Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportSpiral Medical Tube Extrusion Line Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.